Gad Thomas's Form 4 filing
Y-mAbs Therapeutics, Inc. (YMAB) · filed Dec 1, 2021
- Accession no.
- 0001104659-21-145532
- Filed
- Dec 1, 2021
- Trade date
- Nov 29-30, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market sales total $814.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gad ThomasCIK 0001753224 | Director, Officer (See remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2021 | Common Stock | SSaleDisposed | −22,437 | $17.16F1 | −$385,018.92 | 1,462,490 | Indirect | |
| Nov 30, 2021 | Common Stock | SSaleDisposed | −600 | $16.94F3 | −$10,164 | 1,461,890 | Indirect | |
| Nov 30, 2021 | Common Stock | SSaleDisposed | −12,800 | $17.11F4 | −$219,008 | 1,449,090 | Indirect | |
| Nov 30, 2021 | Common Stock | SSaleDisposed | −7,770 | $17.04F5 | −$132,400.8 | 1,441,320 | Indirect | |
| Nov 30, 2021 | Common Stock | SSaleDisposed | −4,000 | $16.98F7 | −$67,920 | 1,437,320 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades at prices ranging from $17.10 to $17.33. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $16.88 to $16.995. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $ 17.00 to $17.22. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $16.87 to $17.190. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F7
This transaction was executed in multiple trades at prices ranging from $16.67 to $17.22. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
Chairman, President and Head of Business Development & Strategy